The potent anti-proliferative effect of 20-EPI analogues of 1,25 dihydroxyvitamin D3 in human breast-cancer MCF-7 cells is related to promoter selectivity

International Journal of Cancer

Volumn 67, Issue 5, 1996, Pages 739-742

  Hansen, Christina MØrk ^a   Danielsson, Carina ^b   Carlberg, Carsten ^b  

^a LEO Pharmaceutical Products ^*  (Denmark)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCITRIOL DERIVATIVE; LEXACALCITOL;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BINDING SITES; BREAST NEOPLASMS; CALCITRIOL; CALCIUM; CELL DIVISION; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROMOTER REGIONS (GENETICS); RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0029739456     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960904)67:5<739::AID-IJC24>3.0.CO;2-Z     Document Type: Article

References (23)

1. 3 inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology, 129, 832-837 (1991).
2. 3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol. cell. Biol., 15, 5789-5799 (1995).
3. 3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem. Pharmacol., 42, 1569-1575 (1991).
4. 3: interplay with retinoid and thyroid hormone signalling. Europ. J. Biochem., 231, 517-527 (1995).
5. 3 receptor in the context of the nuclear receptor superfamily: the central role of retinoid X receptor. Endocrine, 4, 91-105 (1996).
6. CARLBERG, C., BENDIK, I., WYSS, A., MEIER, E., STURZENBECKER, L.J., GRIPPO, J.F. and HUNZIKER, W., Two nuclear signalling pathways for vitamin D. Nature (Lond.), 361, 657-660 (1993).
7. CHEN, J.-Y., PENCO, S., OSTROWSKI, J., BALAGUER, P., PONS, M., STARRETT, J.E., RECZEK, P., CHAMBON, P. and GRONEMEYER, H., RAR-specific agonist/antagonist which dissociate transactivation and API transrepression inhibit anchorage-independent cell proliferation. EMBO J., 14, 1187-1197 (1995).
8. COLSTON, K.W., CHANDER, S.K., MACKAY, A.G. and COOMBES, R.C., Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol., 44, 693-702 (1992a).
9. COLSTON, K.W., MACKAY, A.G., JAMES, S.Y., BINDERUP, L., CHANDER, S. and COOMBES, P.C., EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol., 44, 2273-2280 (1992b).
10. EL-DEIRY, W.S., TOKINO, T., WALDMAN, T., OLINER, J.D., VELCULESCU, V.E., BURRELL, M., HILL, D.E., HEALY, E., REES, J.L., HAMILTON, S.R., KINZLER, K.W. and VOGELSTEIN, B., Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res., 55, 2910-2919 (1995).
11. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res., 55, 2822-2830 (1995).
12. FANJUL, A., DAWSON, M.I., HOBBS, P.D., JONG, L., CAMERON, J.F., HARLEV, E., GRAUPNER, G., LU, X.-P. and PFAHL, M., A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature (Lond.) 372, 107-111 (1994).
13. 3 metabolites. Cancer Res., 43, 4443-4447 (1983).
14. JIANG, H., LIN, J., SU, Z.-Z., COLLART, F.R., HUBERMAN, E. and FISHER, P.B., Induction of differentiation in human promyelotic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene, 9, 3397-3406 (1994).
15. KISSMEYER, A.-M., MATHIASEN, I.S., LATINI, S. and BINDERUP, L., Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP). Endocrine, 3, 263-266 (1995).
16. KRAGBALLE, K., GJERTSEN, B.T., DEHOOP, D., KARLSMARK, T., VAN DE KERKHOE, P.C.M., LARKO, O., TIKJOB, G., NIEBOER, C., STRAND, A. and ROED-PETERSEN, J., Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet, 337, 193-196 (1991).
17. 3 induced differentiation in a human promyelocytic leukemia cell line HL-60: receptor-mediated maturation to macrophage-like cells. J. Cell Biol., 98, 391-398 (1984).
18. 3 analogues is not related to the AP-1 pathway, but related to promoter selectivity. Oncogene, 11, 1853-1858 (1995).
19. 3 correlates well with gene activation. J. cell. Biochem., 61, (1996). (In press).
20. POLS, H.A.P., BIRKENHÄGER, J.C. and VAN LEEUVEN, J.P.T.M., Vitamin D analogues: from molecule to clinical application. Clin. Endocrinol., 40, 285-291 (1994).
21. POTHIER, F., OUELLET, M., JULIEN, J.-P. and GUÉRIN, S.L., An improved CAT assay for promoter analysis in either transgenic mice or tissue culture cells. DNA Cell Biol., 11, 83-90 (1992).
22. SCHRÄDER, M., MÜLLER, K.M., BECKER-ANDRÉ, M. and CARLBERG, C., Response element selectivity for heterodimerization of vitamin D receptors with retinoic acid and retinoid X receptors. J. mol. Endocrinol., 12, 327-339 (1994).
23. 3 response elements formed by inverted palindromes: polarity-directed ligand sensitivity of VDR-RXR heterodimer-mediated transactivation. Mol. cell. Biol., 15, 1154-1161 (1995).